Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Waldenstrom Macroglobulinemia × ibrutinib × Clear all

Phase

Phase 2 12 Phase 1 9 Phase 3 4 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 2 ibrutinib 1 fludarabine phosphate 1 Whole-Body Irradiation 1 Thiotepa 1 Rituximab 1 Melphalan 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Busulfan 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04061512 2024-05-10

RAINBOW

University College, London

Phase 2/3 Recruiting

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡